Despite massive innovations in healthcare of late, drug discovery is still an arduous process, and a huge amount of the natural world remains unexplored for medicinal molecules. Enveda delivers a platform to rapidly probe for new medically active compounds, creating the world's "most diverse biologically annotated dataset of small molecules".
With Enveda's AI and ML-led technology, the chemical structure and biological activity of molecules can be assessed at speed and scale, using high-throughput experiments to generate the dataset that can be rapidly searched for new leads. This represents a breakthrough compared to the long and slow, classical drug discovery process which involves testing one molecule at a time.
Enveda has seen substantial funding that is cited to help progress multiple platform-derived molecules to the clinic, allowing the company to apply its discovery technology to the drug development stages - with targets including inflammation, fibrosis, and neurosensory disorders. With investors including leaders in biotech and technology, it is clear the company is exciting the space and has the potential to make great impact in the future.
Freddie
Company Specialist at Welcome to the Jungle
